New diabetes combo pill shows promise in Late-Stage trial

NCT ID NCT05814406

Completed Disease control Sponsor: JW Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This Phase 3 trial tested whether adding a new drug called JW0201 to standard diabetes medications (metformin and another pill) helps lower blood sugar more effectively. The study included 196 adults with type 2 diabetes whose blood sugar was not well controlled on their current regimen. Participants took either JW0201 or a placebo for 24 weeks, and researchers measured changes in HbA1c, a key blood sugar marker.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JW0201 (a new diabetes drug added to metformin and another medication)
What this could lead to: If successful, this could offer a new add-on treatment option to help people with type 2 diabetes achieve better blood sugar control.
What could go wrong: This is a completed Phase 3 trial, but results are not yet published. The drug may not prove significantly better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Chosun University Hospital

Gwangju, 61452, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.